Abstract:e20526 Background: Immunotherapy with anti-programmed death 1 (PD-1) antibodies has revolutionized the treatment of metastatic and advanced non-small cell lung cancer (NSCLC). However, its application in neoadjuvant scenario has not been well established. Here, we conducted a retrospective study to evaluate the efficacy and safety of neoadjuvant chemo-immunotherapy for patients with potentially resectable NSCLC. Methods: We retrospectively reviewed clinical records of patients with potentially resectable NSCLC (stage IIIA-IIIB) with non-driver gene mutation. The patients underwent neoadjuvant chemo-immunotherapy between March 2019 and October 2020. The outcomes included R0 resection rate, pathologic complete responses (pCR), major pathologic responses (MPR) and safety. The data of whole exome sequencing (WES) and RNA-sequencing (RNA-seq) from tumor samples respectively collected at baseline and at surgery after neoadjuvant therapy were also evaluated. Results: Out of a total of 30 stage III NSCLC patients (29 males and 1 female) at a median age of 56.5 years (range: 46-74), 22 patients (73.3%) had squamous cell carcinoma. Patients received toripalimab/pembrolizumab and platinum-doublet chemotherapy for 2 cycles before surgery. The median duration from final treatment to surgery was 31 days (range: 22-82). One patient refused surgery, and 6 patients did not meet the surgical standards. 23 patients (76.7%) downstaged and reached the surgical standards after neoadjuvant therapy. Out of 23 patients with R0 surgical resection, 16 patients (69.6%) achieved MPR, including 7 patients (30.4%) achieved pCR. The median follow-up duration was 13 months (range: 2-21). As of Jan 20, 2021, no patient had relapsed or died. All grade and grade 3-4 treatment-related adverse events (TRAEs) were reported in 43.3% and 10% of patients, respectively. The most common grade 1-2 TRAEs were transaminase increased (13.3%) and hypothyroidism (16.7%). One patient delayed surgical treatment due to grade 4 transaminase increased. Baseline expression of type-I HLA molecule was lower in MPR/pCR group than that in non-MPR group (HLA-F: p = 0.052). After neoadjuvant therapy, the expression of HLA-F in MPR/pCR patients was significantly increased (p = 0.0047) while the expression of HLA-B in non-MPR patients was decreased (p = 0.032) compared to that of the baseline, suggesting that neoadjuvant therapy may potentially facilitate specific antigen presentation in the tumor tissues of patients with MPR/pCR. Conclusions: Neoadjuvant chemo-immunotherapy for potentially resectable NSCLC is a tolerable treatment with an improved surgical resection rate, MPR and pCR. Based on our findings, a prospective, single arm, phase II study of neoadjuvant toripalimab combined with platinum-doublet chemotherapy is currently being conducted (NCT04144608). Clinical trial information: NCT04324151.

Efficacy and safety of PD-1/PD-L1 inhibitor plus platinum-based chemotherapy vs. platinum-based chemotherapy alone in patients with previously untreated advanced large-cell neuroendocrine cancer of the lung.

Efficacy and Safety of PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.

Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.

Immunotherapy Combined with Chemotherapy Versus Chemotherapy Alone As the First‐line Treatment of PD‐L1‐negative and Driver‐gene‐negative Advanced Nonsquamous Non‐small‐cell Lung Cancer: an Updated Systematic Review and Meta‐analysis

Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors Versus Platinum-Based Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer: a Meta Analysis of Randomized Controlled Trials.

Randomized Clinical Trial of Pembrolizumab Vs Chemotherapy for Previously Untreated Chinese Patients with PD‐L1‐positive Locally Advanced or Metastatic Non–small‐cell Lung Cancer: KEYNOTE‐042 China Study

Platinum-based Chemotherapy (chemo) with CS1001, an Anti-Pd-l1 Antibody, for First-Line Advanced Non-Small Cell Lung Cancer (NSCLC): Preliminary Results from Phase Ib Cohorts of CS1001-101 Study.

JCSE01.26 PD-1 Inhibitor Plus Chemotherapy As 2nd/subsequent Line Setting Demonstrate Superior Efficacy over PD-1 Inhibitor Alone in Pts of Advanced NSCLC

P1.04-46 PD-1 Inhibitor Plus Chemotherapy As 2nd/subsequent Line Setting Demonstrate Superior Efficacy over PD-1 Inhibitor Alone in Pts of Advanced NSCLC

Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

The efficacy and safety of neoadjuvant anti-PD-1 inhibitor combined with platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer.

A comparative study of the efficacy and safety of PD-1/L1 inhibitor and platinum-containing dual-agent chemotherapy in patients with advanced non-small cell lung cancer resistant to EGFR-TKIs

PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Nab-Paclitaxel with or Without Bevacizumab As Second-Line Therapy or Beyond for Patients with Metastatic Non-Small-cell Lung Cancer.

Immunotherapy or Antiangiogenic Therapy Plus Chemotherapy As First‐line Treatment of Patients with PD‐L1(‐) Advanced Non‐squamous Non‐small Cell Lung Cancer in a Chinese Cohort

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

Immunotherapy combined with chemotherapy for patients with pulmonary large cell neuroendocrine carcinoma

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials

The Efficacy and Safety of PD-1 Inhibitors in Combination with or Without Chemotherapy And/or Bevacizumab As Second Line Treatment or Beyond in Non-Small Cell Lung Cancer: Preliminary Data from a Real-World Setting.

Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer